Three years sustained complete remission achieved in a primary refractory ALK-positive anaplastic T large cell lymphoma treated with crizotinib
The prognosis of the primary refractory anaplastic lymphoma kinase (ALK+) anaplastic T large cell lymphoma is ominous. The identification of molecular targets with potential to drive oncogenesis remains a cornerstone for the designing of new selective cancer therapies. Crizotinib is a selective ATP-...
Main Authors: | Carolina Valeria Mahuad, Maria de los Ángeles Vicente Repáraz, Marta E. Zerga, María Florencia Aizpurúa, Claudia Casali, Gonzalo Garate |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2016-06-01
|
Series: | Rare Tumors |
Subjects: | |
Online Access: | http://www.pagepress.org/journals/index.php/rt/article/view/6266 |
Similar Items
-
Unusual Late Relapse of ALK-Positive Anaplastic Large Cell Lymphoma Successfully Cleared Using the ALK-Inhibitor Crizotinib: Case Report
by: Dennis Christoph Harrer, et al.
Published: (2020-10-01) -
Anaplastic Lymphoma Kinase in Cutaneous Malignancies
by: Severine Cao, et al.
Published: (2017-09-01) -
Clinical Efficacy of Crizotinib in Treatment of Patients with Advanced NSCLC
by: Emei GAO, et al.
Published: (2016-03-01) -
Treatment of Patients with ALK Gene Rearranged Non-small Cell Lung Cancer
after Resistance to Crizotinib
by: Tao JIANG, et al.
Published: (2015-02-01) -
A patient previously treated with ALK inhibitors for central nervous system lesions from ALK rearranged lung cancer: a case report
by: Kashima J, et al.
Published: (2016-10-01)